Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7276 to 7290 of 7711 results

  1. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued

  2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

    This guidance has been updated and replaced by NICE diagnostics guidance 58.

    Diagnostics guidance
    Published
    19 December 2018

  3. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Health app: Sleepio for adults with poor sleep (MIB129)

    This advice has been updated and replaced by NICE medical technologies guidance 70.

    Medtech innovation briefing
    Published
    9 November 2017

  5. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    In development [GID-TA10917] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

    Medtech innovation briefing
    Published
    8 November 2023

  8. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

  9. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Technology appraisal guidance
    Published
    19 May 2021

  10. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  13. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  14. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  15. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development